Event Details

October 21, 2021 | 2:30pm ET

Process Development to Set Up for Clinical Success

Ed Samuel - Senior Vice President, Technical Operations Achilles Therapeutics

The Importance of Early Manufacturing Decisions for Building a Commercially-Scalable Personalised, Precision T Cell Therapy

• Addressing the challenges of cell therapy manufacturing by investing early in the design of a fully-closed and automated process for industrial scale-up
• Building a scalable and automated process to support large scale expansion and a reduction in manufacturing timelines and costs
• Strategies for designing a clonal neoantigen T cell therapy (cNeT) with specificity for multiple targets and maintaining potency and fitness